| Literature DB >> 29403741 |
Patrícia Severino1, George G G de Oliveira2, Humberto G Ferraz2, Eliana B Souto3,4, Maria H A Santana1.
Abstract
The purpose of this work was to introduce a new concept of coated pellets containing chitosan microspheres loaded with didadosine for oral administration, aiming at reducing the frequency of administration and improving the bioavailability by a suitable release profile. Chitosan microspheres were produced under fluidized bed, followed by extrusion and spheronization to obtain pellets with a mean diameter of about 1 mm. The pellets were then coated with Kollidon® VA64 and Kollicoat® MAE100P in water dispersion to depict a sustained release profile. Conventional hard gelatine capsules were loaded with these pellets and tested in vitro for their release profile of didadosine. Dissolution testing confirmed that chitosan microsphere pellets provides appropriate sustained release up to 2 h behavior for didanosine.Entities:
Keywords: Chitosan; Coating; Didanosine; Gastro-resistance; Microspheres; Pellets
Year: 2012 PMID: 29403741 PMCID: PMC5760906 DOI: 10.1016/j.jpha.2012.02.005
Source DB: PubMed Journal: J Pharm Anal ISSN: 2214-0883
Composition of sub-coating and outer-coating solutions used for the production of pellets (% m/v).
| Coatings | Composition | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|---|---|---|---|---|---|---|---|---|
| Sub-coating | Kollidon® VA64 (%) | 5 | – | 5 | 10 | 10 | 10 | 10 |
| Water (mL) | 30 | – | 60 | 100 | 30 | 30 | 30 | |
| Outer-coating | Kollicoat® MAE 100 P (%) | 10 | 20 | 30 | 20 | 10 | 20 | 30 |
| Propylene glycol (%) | 2.25 | 2.25 | 2.25 | 2.5 | 1.5 | 1.5 | 1.5 | |
| Magnesium trisilicate (%) | 4 | 4 | 4 | 4 | 0.5 | 0.5 | 0.5 | |
| Titanium dioxide (%) | – | – | – | 2 | 0.5 | 0.5 | 0.5 | |
| Alcohol (mL) | – | – | – | – | 100 | 100 | 100 | |
| Water (mL) | 30 | 50 | 60 | 100 | ||||
Pellets produced by fluidized bed.
Pellets produced by extrusion/spheronization.
Geometric parameters of pellets produced by fluidized bed (Formulations 1*–4*) and by extrusion/spheronization (Formulations 5**–7**) in comparison to a commercial formulation.
| Formulation | Elongation | Sphericity | Feret diameter (mm) |
|---|---|---|---|
| 1* | 1.70±0.82 | 0.90±0.24 | 0.25±0.18 |
| 2* | 1.58±0.71 | 0.92±0.25 | 0.19±0.16 |
| 3* | 1.63±0.72 | 0.81±0.20 | 0.70±0.38 |
| 4* | 1.48±0.46 | 0.81±0.28 | 0.49±0.29 |
| 5** | 1.23±0.26 | 0.76±0.11 | 1.11±0.16 |
| 6** | 1.45±1.20 | 0.66±0.17 | 1.28±0.48 |
| 7** | 1.25±0.48 | 0.74±0.15 | 1.05±0.26 |
| Videx® EC | 1.43±0.31 | 0.86±0.10 | 1.52±0.28 |
Figure 1Photographs of pellets obtained by stereoscopy.
Figure 2Release profile of didanosine vs time from hard gelatine capsules containing pellets produced by fluidized bed (Formulations 1–4).
Figure 3Release profiles of didanosine vs time from hard gelatine capsules containing pellets produced by extrusion/spheronization (Formulations 5–7).